Takeda Pharmaceutical (TAK) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Takeda Pharmaceutical (TAK) over the last 9 years, with Mar 2025 value amounting to $2.5 billion.

  • Takeda Pharmaceutical's Cash & Equivalents fell 18.29% to $2.5 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $2.5 billion, marking a year-over-year decrease of 18.29%. This contributed to the annual value of $2.5 billion for FY2025, which is 20.36% down from last year.
  • According to the latest figures from FY2025, Takeda Pharmaceutical's Cash & Equivalents is $2.5 billion, which was down 20.36% from $3.2 billion recorded in FY2024.
  • In the past 5 years, Takeda Pharmaceutical's Cash & Equivalents registered a high of $9.1 billion during FY2021, and its lowest value of $2.5 billion during FY2025.
  • Its 3-year average for Cash & Equivalents is $3.2 billion, with a median of $3.2 billion in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 55.37% in 2021, then tumbled by 47.82% in 2023.
  • Yearly analysis of 5 years shows Takeda Pharmaceutical's Cash & Equivalents stood at $9.1 billion in 2021, then fell by 16.96% to $7.6 billion in 2022, then plummeted by 47.82% to $3.9 billion in 2023, then declined by 19.62% to $3.2 billion in 2024, then fell by 20.36% to $2.5 billion in 2025.